Declaration of interests
RS, PWH, TTB
PCT
PCT: Merck has provided her institution with funding for her research; Gilead and Lilly have also provided her institution with funding for her to conduct industry-sponsored clinical trials. PWH: Gilead has provided funding to his institution, and Merck has provided donation of study drug for NIH-sponsored trial. He has also received consulting fees and other support from Viiv Healthcare, Biotron, Gilead and Longeveron. JD is an inventor on patents related to the composition of matter and/or use of pro-resolving mediators some of which are licensed by Brigham and Women's Hospital or Queen Mary University of London for clinical development. AG: NIH, UNITAID and CDC have provided funding to her institution. TTB has received consulting fees from ViiV Healthcare, Theratechnologies, Janssen, Merck and Gilead. JAA: Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, GSK, Janssen, Merck, Pfizer, Regeneron and Viiv Healthcare have provided her institution with funding. RS: funding for current work was provided to institution by NIH and the ACTG network. The remaining authors have no conflicts of interest to declare.